Intuitive Surgical Q2 revenue rises 19% as da Vinci placements surge
Intuitive Surgical, the Sunnyvale-based company behind the da Vinci robotic surgical platform, reported second-quarter 2026 revenue of $2.89 billion, a 19% increase on the $2.44 billion recorded in the same period a year earlier. GAAP net income attributable to the company reached $818 million, or $2.29 per diluted share, up from $658 million, or $1.81 per diluted share, in Q2 2025.
The quarter's growth was driven by a combination of higher procedure volumes, an expanding installed base, and increased leasing revenue. Instruments and accessories, the consumables-like revenue stream that tracks directly with procedure activity, rose 18% to $1.73 billion, while systems revenue climbed to $685 million from $575 million a year earlier. The company ended the quarter with $8.63 billion in cash, cash equivalents, and investments.
Procedure growth and system placements
Worldwide procedures across da Vinci and Ion combined grew approximately 16% compared with Q2 2025, with da Vinci up around 15% and Ion, the company's endoluminal bronchoscopy platform, up approximately 36%. The company placed 468 da Vinci systems in the quarter, compared with 395 a year earlier, of which 246 were the newer da Vinci 5 model. The da Vinci installed base now stands at 11,710 systems globally, a 12% year-on-year increase. Ion's installed base grew 21% to 1,096 systems.
Chief executive Dave Rosa said the results reflected the strength of Intuitive's portfolio, spanning da Vinci, Ion, and what he described as growing digital solutions. The company did not elaborate on specific digital product metrics in the release.
A one-off benefit of $28 million after tax, or $0.08 per diluted share, related to refunds on tariffs previously paid under the International Emergency Economic Powers Act, was included in both GAAP and non-GAAP net income for the quarter. On a non-GAAP basis, net income was $1.00 billion, or $2.80 per diluted share.
Tariff risk and full-year outlook
Intuitive maintained its full-year 2026 guidance for da Vinci procedure growth of approximately 13.5% to 15.5%, saying it expects to land near the midpoint of that range. Non-GAAP gross profit margin guidance of 68.0% to 69.0% already incorporates an estimated 1.0 percentage point drag from tariffs currently in place. The company warned that any additional tariff measures beyond current expectations could have a material adverse effect on results, noting that a significant majority of its instruments and accessories are manufactured in Mexico, and most endoscopes in Germany.
The tariff exposure is a notable overhang for a business whose margin profile is otherwise enviable. Intuitive's market position in robotic-assisted surgery remains formidable: no competitor has yet matched the breadth of its installed base or the depth of its procedure data. However, the competitive landscape is shifting. Medtronic's Hugo system has received regulatory clearance in a number of markets outside the United States, and Johnson and Johnson's Ottava platform is advancing through its clinical and regulatory programme. Domestic Chinese competitors, supported by government procurement policies, are also gaining traction in that market, a risk Intuitive acknowledges explicitly in its regulatory filings.
For investors, the headline numbers reinforce the company's durable growth profile. The key questions heading into the second half of 2026 are whether tariff relief persists or reverses, how quickly da Vinci 5 adoption converts to higher average selling prices, and whether Ion's rapid percentage growth in a still-small installed base begins to contribute meaningfully to overall revenue.